San Diego biotech Halozyme Therapeutics Inc. has appointed Mark J. Gergen as senior vice president and chief operating officer.

Gergen joins Halozyme from Mirati Therapeutics, a local biotech working on targeted oncology medicines, where he served as executive vice president and chief operations officer.

Gergen will be responsible for corporate development, including the management of Halozyme’s Enhanze platform collaborations, and the management of global product teams commercializing Halozyme’s anti-cancer pipeline, the company said.

He will report to Dr. Helen Torley, president and CEO of Halozyme.

"Mark brings a wealth of business development and operational experience that will be essential as we execute our plan to accelerate growth of the Enhanze platform and develop and commercialize multiple oncology drugs," Torley said in a statement. "With more than 20 years of health care and biotech experience, he will be a strong addition to our management team as we execute our growth strategy."

Before Mirati, Gergen spent seven years at Amylin Pharmaceuticals as a member of the executive committee, where he led corporate development and alliances.

Halozyme (Nasdaq: HALO) is one of San Diego’s larger public biotechs, with a market cap of $1.3 billion. The company is developing drugs to treat cancer, as well as a drug delivery platform that makes it easier and more convenient for patients to receive certain treatments.